research paper: Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia
Abstract
Altered expression of histone deacetylases (HDACs) is a common feature in several human malignancies and may represent an interesting target for cancer treatment, including haematological malignancies. We evaluated the mRNA gene expression profile of 12 HDAC genes by quantitative real-time polymerase chain reaction in 94 consecutive childhood acute lymphoblastic leukaemia (ALL) samples and its association with clinical/biological features and survival. ALL samples showed higher expression levels of HDAC2, HDAC3, HDAC8, HDAC6 and HDAC7 when compared to normal bone marrow samples. HDAC1 and HDAC4 showed high expression in T-ALL and HDAC5 was highly expressed in B-lineage ALL. Higher than median expression levels of HDAC3 were associated with a significantly lower 5-year event-free survival (EFS) in the overall group of patients (P = 0·03) and in T-ALL patients (P = 0.01). HDAC7 and HADC9 expression levels higher than median were associated with a lower 5-year EFS in the overall group (P = 0.04 and P = 0.003, respectively) and in B-lineage CD10-positive patients (P = 0.009 and P = 0·005, respectively). Our data suggest that higher expression of HDAC7 and HDAC9 is associated with poor prognosis in childhood ALL and could be promising therapeutic targets for the treatment of refractory childhood ALL.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
HDAC8 is frequently overexpressed in different tumor types.
“HDAC8 is frequently overexpressed in different tumor types (Lehmann et al., 2014;Moreno et al., 2010;Oehme et al., 2009).”
From HDACs and the epigenetic plasticity of cancer cells: target the complexity (2022) · cites this paper as Moreno et al., 2010
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860 · see citing works
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1779 · Cited by 2,211 · see citing works
Bernstein, B. E., Meissner, A., & Lander, E. S. (2007) · Cell · doi:10.1016/j.cell.2007.01.033 · Cited by 2,086 · see citing works
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866 · see citing works
Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction?
Baylin, S. B., & Ohm, J. E. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1799 · Cited by 1,632 · see citing works
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-10-1247 · Cited by 1,365 · see citing works
HDAC family: What are the cancer relevant targets?
Witt, O., Deubzer, H. E., Milde, T., & Oehme, I. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.08.016 · Cited by 1,069 · see citing works
Olsen, E. A., Kim, Y. H., Kuzel, T. M., Pacheco, T. R., Foss, F. M., Parker, S. R. S., Frankel, S. R., Chen, C., Ricker, J. L., Arduino, J. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2434 · Cited by 1,057 · see citing works
Histone deacetylases and cancer
Glozak, M. A., & Seto, E. (2007) · Oncogene · doi:10.1038/sj.onc.1210610 · Cited by 1,031 · see citing works
The role of histone deacetylases (HDACs) in human cancer
Ropero, S., & Esteller, M. (2007) · Molecular Oncology · doi:10.1016/j.molonc.2007.01.001 · Cited by 1,007 · see citing works
Histone Deacetylase Inhibitors in Cancer Therapy
Lane, A. A., & Chabner, B. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1291 · Cited by 880 · see citing works
Epigenetics: A Historical Overview
Holliday, R. (2006) · Epigenetics · doi:10.4161/epi.1.2.2762 · Cited by 712 · see citing works
HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics
Gallinari, P., Marco, S. D., Jones, P., Pallaoro, M., & Steinkühler, C. (2007) · Cell Research · doi:10.1038/sj.cr.7310149 · Cited by 678 · see citing works
Class II histone deacetylases: versatile regulators
Verdin, E., Dequiedt, F., & Kasler, H. G. (2003) · Trends in Genetics · doi:10.1016/s0168-9525(03)00073-8 · Cited by 664 · see citing works
de Haar-Holleman, A., Cheok, M. H.-C., den Boer, M. L., Yang, W., Veerman, A. J. P., Kazemier, K. M., Pei, D., Cheng, C., Pui, C., Relling, M. V., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033513 · Cited by 629 · see citing works
Classification of pediatric acute lymphoblastic leukemia by gene expression profiling
Ross, M. E., Zhou, X., Song, G., Shurtleff, S. A., Girtman, K., Williams, W. K., Liu, H., Mahfouz, R. A., Raimondi, S. C., Lenny, N. T., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0338 · Cited by 589 · see citing works
Weichert, W., Roske, A.-E., Gekeler, V., Beckers, T. L., Stephan, C., Jung, K., Fritzsche, F., Niesporek, S., Denkert, C., Dietel, M., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604199 · Cited by 478 · see citing works
HDAC expression and clinical prognosis in human malignancies
Weichert, W. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.10.047 · Cited by 411 · see citing works
Bradbury, C. A., Khanim, F. L., Hayden, R., Bunce, C. M., White, D. A., Drayson, M. T., Craddock, C., & Turner, B. M. (2005) · Leukemia · doi:10.1038/sj.leu.2403910 · Cited by 403 · see citing works
Byrd, J. C. (2004) · Blood · doi:10.1182/blood-2004-05-1693 · Cited by 400 · see citing works
Weichert, W., Roske, A.-E., Niesporek, S., Noske, A., Buckendahl, A., Dietel, M., Gekeler, V., Boehm, M., Beckers, T. L., & Denkert, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0990 · Cited by 362 · see citing works
Weichert, W., Roske, A.-E., Gekeler, V., Beckers, T. L., Ebert, M. P., Pross, M., Dietel, M., Denkert, C., & Röcken, C. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70004-4 · Cited by 361 · see citing works
Expression profile of class I histone deacetylases in human cancer tissues
Nakagawa, M., Oda, Y., Eguchi, T., Aishima, S.-I., Yao, T., Hosoi, F., Basaki, Y., Ono, M., Kuwano, M., Tanaka, M., et al. (2007) · Oncology Reports · doi:10.3892/or.18.4.769 · Cited by 343 · see citing works
Apoptosis of T Cells Mediated by Ca 2+ -Induced Release of the Transcription Factor MEF2
Youn, H., Sun, L., Prywes, R., & Liu, J. O. (1999) · Science · doi:10.1126/science.286.5440.790 · Cited by 258 · see citing works
Cloning and characterization of a histone deacetylase, HDAC9
Zhou, X., Marks, P. A., Rifkind, R. A., & Richon, V. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191375098 · Cited by 245 · see citing works
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia
Garcia‐Manero, G., Assouline, S. E., Cortes, J. E., Estrov, Z. E., Kantarjian, H. M., Yang, H., Newsome, W. M., Miller, W. H., Rousseau, C., Kalita, A., et al. (2008) · Blood · doi:10.1182/blood-2007-10-115873 · Cited by 232 · see citing works
Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review
Acharya, M. R., Sparreboom, A., Venitz, J., & Figg, W. D. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.014167 · Cited by 231 · see citing works
Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis
Krusche, C. A., W�lfing, P., Kersting, C., Vloet, A. J., B�cker, W., Kiesel, L., Beier, H. M., & Alfer, J. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-1668-2 · Cited by 230 · see citing works
The fundamental role of epigenetics in hematopoietic malignancies
Galm, O., Herman, J. G., & Baylin, S. B. (2005) · Blood Reviews · doi:10.1016/j.blre.2005.01.006 · Cited by 229 · see citing works
Integration of calcineurin and MEF2 signals by the coactivator p300 during T‐cell apoptosis
Youn, H., Chatila, T. A., & Liu, J. O. (2000) · The EMBO Journal · doi:10.1093/emboj/19.16.4323 · Cited by 223 · see citing works
HDAC3: taking the SMRT-N-CoRrect road to repression
Karagianni, P., & Wong, J. (2007) · Oncogene · doi:10.1038/sj.onc.1210612 · Cited by 221 · see citing works
Osada, H., Tatematsu, Y., Saito, H., Yatabe, Y., Mitsudomi, T., & Takahashi, T. (2004) · International Journal of Cancer · doi:10.1002/ijc.20395 · Cited by 213 · see citing works
Kato, H., Tamamizu‐Kato, S., & Shibasaki, F. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406320200 · Cited by 196 · see citing works
Wang, L., de Zoeten, E. F., Greene, M. I., & Hancock, W. W. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd3031 · Cited by 186 · see citing works
Weichert, W., Denkert, C., Noske, A., et al. (2008) · Neoplasia · doi:10.1593/neo.08474 · Cited by 181 · see citing works
Epigenetic aberrations and cancer.
Ducasse, M., & Brown, M. A. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-60 · Cited by 165 · see citing works
Youn, H., & Liu, J. O. (2000) · Immunity · doi:10.1016/s1074-7613(00)00010-8 · Cited by 161 · see citing works
Lucio-Eterovic, A. K., Cortez, M. A. A., Valera, E. T., Motta, F., Queiróz, R. G. D. P., Machado, H. R., Carlotti, C. G., Neder, L., Scrideli, C. A., & Tone, L. G. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-243 · Cited by 156 · see citing works
Self-citationHistone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines
Sakajiri, S., Kumagai, T., Kawamata, N., et al. (2005) · Experimental Hematology · doi:10.1016/j.exphem.2004.09.008 · Cited by 149 · see citing works
Matthews, S. A., Liu, P., Spitaler, M., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.4.1569-1577.2006 · Cited by 147 · see citing works
The Histone Deacetylase 9 Gene Encodes Multiple Protein Isoforms
Petrie, K. R., Guidez, F., Howell, L., Healy, L. E., Waxman, S., Greaves, M. F., & Zelent, A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212935200 · Cited by 146 · see citing works
Cheng, L., Qasba, P., Vanguri, P., & Thiede, M. A. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200007)184:1 · Cited by 136 · see citing works
Histone deacetylase 1, 2, 6 and acetylated histone H4 in B‐ and T‐cell lymphomas
Marquard, L., Poulsen, C. B., Gjerdrum, L. M. R., Brown, P. D. N., Christensen, I. J., Jensen, P. B., Sehested, M., Johansen, P., & Ralfkiaer, E. M. (2009) · Histopathology · doi:10.1111/j.1365-2559.2009.03290.x · Cited by 134 · see citing works
Klimek, V. M., Fircanis, S., Maslak, P. G., Guernah, I., Baum, M., Wu, N. F., Panageas, K. S., Wright, J. J., Pandolfi, P. P., & Nimer, S. D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0318 · Cited by 130 · see citing works
Ouaïssi, M., Sielezneff, I., Silvestre, R., Sastre, B., Bernard, J., Simony-Lafontaine, J., Payan, M. J., Dahan, L., Pirró, N., Seitz, J. F., et al. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-9940-z · Cited by 122 · see citing works
Epigenetics, disease, and therapeutic interventions
Lu, Q., Qiu, X., Hu, N., Wen, H., Su, Y., & Richardson, B. C. (2006) · Ageing Research Reviews · doi:10.1016/j.arr.2006.07.001 · Cited by 121 · see citing works
Histone Deacetylase in Carcinogenesis and Its Inhibitors as Anti-cancer Agents
Kim, D. H., Kim, M., & Kwon, H.-J. (2003) · BMB Reports · doi:10.5483/bmbrep.2003.36.1.110 · Cited by 121 · see citing works
CHOI, Y.-W., Bae, S. M., Kim, Y., et al. (2007) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2007.00834.x · Cited by 120 · see citing works
Histone deacetylases as therapeutic targets in hematologic malignancies
Melnick, A. M., & Licht, J. D. (2002) · Current Opinion in Hematology · doi:10.1097/00062752-200207000-00010 · Cited by 117 · see citing works
Gruffat, H., Manet, É., & Sergeant, A. (2002) · EMBO Reports · doi:10.1093/embo-reports/kvf031 · Cited by 114 · see citing works
Blum, K. A., Advani, A., FERNANDEZ, L. A. V., van der Jagt, R., Brandwein, J. M., Kambhampati, S., Kassis, J., Davis, M. E., Bonfils, C., Dubay, M., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07881.x · Cited by 112 · see citing works
Marquard, L., Gjerdrum, L. M. R., Christensen, I. J., Jensen, P. B., Sehested, M., & Ralfkiaer, E. M. (2008) · Histopathology · doi:10.1111/j.1365-2559.2008.03109.x · Cited by 107 · see citing works
Gloghini, A., Buglio, D., Khaskhely, N. M., Georgakis, G. V., Orlowski, R. Z., Neelapu, S. S., Carbone, A., & Younes, A. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07887.x · Cited by 91 · see citing works
Brandalise, S. R., Pinheiro, V. R. P., Aguiar, S. S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6115 · Cited by 84 · see citing works
Self-citationSwanson, B. J., Jäck, H., & Lyons, G. E. (1998) · Molecular Immunology · doi:10.1016/s0161-5890(98)00058-3 · Cited by 82 · see citing works
Bakin, R. E., & Jung, M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m409271200 · Cited by 73 · see citing works
Esau, C., Boes, M. L., Youn, H., Tatterson, L. E., Liu, J. O., & Chen, J. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.10.1449 · Cited by 64 · see citing works
Romanski, A., Bacic, B., Bug, G., Pfeifer, H., Gül, H., Remiszewski, S., Hoelzer, D. F., Atadja, P. W., Ruthardt, M., & Ottmann, O. G. (2004) · PubMed · Cited by 59 · see citing works
Scrideli, C. A., Assumpção, J. G., Ganazza, M., et al. (2009) · Haematologica · doi:10.3324/haematol.2008.003137 · Cited by 57 · see citing works
Self-citationTsapis, M., Lieb, M., Manzo, F., Shankaranarayanan, P., Herbrecht, R., Lutz, P., & Gronemeyer, H. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.03.009 · Cited by 49 · see citing works
Epigenetic therapies in haematological malignancies: Searching for true targets
Altucci, L., & Minucci, S. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.03.001 · Cited by 44 · see citing works
Rao, S., Karray, S., Gackstetter, E. R., & Koshland, M. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.40.26123 · Cited by 42 · see citing works
Cortez, M. A., Scrideli, C. A., Yunes, J. A., et al. (2009) · Pediatric Blood & Cancer · doi:10.1002/pbc.22220 · Cited by 31 · see citing works
Self-citationSodium butyrate enhances the cytotoxic effect of antineoplastic drugs in human lymphoblastic T-cells
dos Santos, M. P., Schwartsmann, G., Roesler, R., et al. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.07.003 · Cited by 23 · see citing works
Sasaki, K., Yamagata, T., & Mitani, K. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2007.00699.x · Cited by 18 · see citing works
NF-κB family of transcription factor facilitates gene conversion in chicken B cells
Kim, Y., & Tian, M. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.07.027 · Cited by 18 · see citing works
Satyaraj, E., & Storb, U. (1998) · PubMed · Cited by 16 · see citing works
Mef2 Proteins, Required for Muscle Differentiation, Bind an Essential Site in the Ig λ Enhancer
Satyaraj, E., & Storb, U. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.9.4795 · Cited by 16 · see citing works
Yang, X. H., Huang, Y., Chen, J. L., Xie, J., Sun, X. S., & Lussier, Y. A. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-s9-s6 · Cited by 11 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404 · see citing works
Marked for death: Targeting epigenetic changes in cancer
Pfister, S. X., & Ashworth, A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.256 · Cited by 288 · see citing works
Long, J., Fang, W. Y., Chang, L., Gao, W. H., Shen, Y., Jia, M. Y., Zhang, Y. X., Wang, Y., Dou, H. B., Zhang, W. J., et al. (2017) · Leukemia · doi:10.1038/leu.2017.130 · Cited by 78 · see citing works
Hua, W.-K., Qi, J., Cai, Q., Carnahan, E., Ayala Ramirez, M., Li, L., Marcucci, G., & Kuo, Y.-H. (2017) · Blood · doi:10.1182/blood-2017-03-771386 · Cited by 57 · see citing works
HDACs and the epigenetic plasticity of cancer cells: target the complexity
Brancolini, C., Gagliano, T., & Minisini, M. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108190 · Cited by 55 · see citing works
Insights into regulators of p53 acetylation
Nagasaka, M., Miyajima, C., Aoki, H., Aoyama, M., Morishita, D., Inoue, Y., & Hayashi, H. (2022) · Cells · doi:10.3390/cells11233825 · Cited by 45 · see citing works
- Authors
- Moreno, D. A., Scrideli, C. A., Cortez, M. A. A., De Paula Queiroz, R., Valera, E. T., Da Silva Silveira, V., Yunes, J. A., Brandalise, S. R., & Tone, L. G.
- Affiliations
- Universidade de São Paulo (BR)
- Corresponding author
- Scrideli, Carlos Alberto
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2010-09
- Volume
- 150
- Issue
- 6
- Pages
- 665-673
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W1547154484
- Cited by
- 208
- References
- 69
- Citations by year
- 2026: 3 · 2025: 10 · 2024: 23 · 2023: 12 · 2022: 14 · 2021: 16 · 2020: 18 · 2019: 10 · 2018: 11 · 2017: 17 · 2016: 14 · 2015: 12 · 2014: 17 · 2013: 12 · 2012: 9
- FWCI
- 9.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- British Journal of Haematology (publishedVersion)
- PubMed (publishedVersion)
- Scientific Electronic Library Online (São Paulo Research Foundation, Latin American and Caribbean Center on Health Sciences Information, Conselho Nacional de Desenvolvimento Científico e Tecnológico) (publishedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Acute Lymphoblastic Leukemia research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- histone deacetylase, HDAC3, HDAC7, HDAC9, childhood acute lymphoblastic leukemia, gene expression profiling, event-free survival, prognosis, T-cell acute lymphoblastic leukemia, therapeutic target, refractory leukemia
- MeSH terms
- Histone Deacetylase 3, Adolescent, Bone Marrow, Child, Child, Preschool, Female, Histone Deacetylases, Humans, Infant, Male, Prognosis, Repressor Proteins, RNA, Messenger, RNA, Neoplasm, Biomarkers, Tumor, Survival Analysis, Reverse Transcriptase Polymerase Chain Reaction, Gene Expression Profiling, Precursor Cell Lymphoblastic Leukemia-Lymphoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
